Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Early-onset systemic lupus erythematosus in a patient with an inborn error of immunity caused by a NRAS mutation and treated with telitacicept.
Kang Z et al.
Molecular and Cellular Pediatrics, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Tantawy SI et al.
Blood Cancer Journal, 2025
The crystal and cryo-EM structures of PLCγ2 reveal dynamic interdomain recognitions in autoinhibition.
Shin YC et al.
Science Advances, 2024
Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.
Yang Z et al.
Arthritis & Rheumatology (hoboken, N.j.), 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.
Aslan B et al.
Blood Advances, 2024
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
IGH Translocations in Chinese Patients With Chronic Lymphocytic Leukemia: Clinicopathologic Characteristics and Genetic Profile.
Li Q et al.
Frontiers in Oncology, 2022
The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration.
Jackson JT et al.
The Journal of Biological Chemistry, 2021
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE et al.
Frontiers in Immunology, 2021
Phospholipase C families: Common themes and versatility in physiology and pathology.
Katan M et al.
Progress in Lipid Research, 2020
Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations.
Martín-Nalda A et al.
Journal of Clinical Immunology, 2020
Structural insights and activating mutations in diverse pathologies define mechanisms of deregulation for phospholipase C gamma enzymes.
Liu Y et al.
Ebiomedicine, 2020
Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.
Magno L et al.
Alzheimer's Research & Therapy, 2019
Cool-temperature-mediated activation of phospholipase C-γ2 in the human hereditary disease PLAID.
Schade A et al.
Cellular Signalling, 2016
Dysfunction of phospholipase Cγ in immune disorders and cancer.
Koss H et al.
Trends in Biochemical Sciences, 2014
BANK1 and BLK act through phospholipase C gamma 2 in B-cell signaling.
Bernal-Quirós M et al.
Plos One, 2013
A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.
Zhou Q et al.
American Journal of Human Genetics, 2012
Platelet hyperreactivity and a prothrombotic phenotype in mice with a gain-of-function mutation in phospholipase Cgamma2.
Elvers M et al.
Journal of Thrombosis and Haemostasis : Jth, 2010
Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry.
Yu P et al.
Immunity, 2005